Any patient can access Signos' system, which uses an AI platform and an off-the-shelf continuous glucose monitor, or CGM, ...

Signos’s glucose-tracking system uses AI and real-time data to guide healthier habits—no prescription required.

The FDA cleared the first glucose monitoring system specifically designed for weight management from Signos, providing a new ...

The FDA has approved Signos, the first glucose monitoring app using AI to help users lose weight and track real-time food reactions.

The FDA has approved Sisnos’s continuous glucose monitoring (CGM) system for consumer use beyond diabetes management, ...

Signos Inc. landed U.S. FDA clearance for its over-the-counter glucose monitoring system, which combines Dexcom Inc.'s ...

In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval ...

The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous ...

The FDA approved the first over-the-counter glucose monitoring system designed to help with weight management. Developed by health technology company Signos, the system combines the Stelo by Dexcom ...

The FDA on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. The Signos ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...